Clinical trials: T2DM (Type 2 Diabetes Mellitus)
Type 2 Diabetes
A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes
The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes
- Trial name
- MAD (NCT00747175)
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Chronic Kidney Diseases
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.
- Trial name
- NCT04990427
- Testing
- CLBS201
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Lisata Therapeutics, Inc.
Type 2 Diabetes, Overweight and Obese Adults
Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM
This study evaluates the efficacy of D-Chiro-Inositol (DCI) as an add-on therapy to metformin in improving insulin resistance, measured by the HOMA index, in people with overweight or obesity and type 2 diabetes mellitus (T2DM).
- Trial name
- DIACHIRO (NCT06860841)
- Testing
- D-Chiro-Inositol Combined with Metformin
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Campus Bio-Medico University
Type 2 Diabetes Mellitus, Periodontitis
Integrated Diabetes and Oral Health Care in Oman
Type 2 diabetes mellitus (T2DM) and periodontal (gum) disease are closely related conditions that may negatively affect each other. However, oral health is not routinely integrated into diabetes self-management education.
- Conditions
- Type 2 Diabetes Mellitus, Periodontitis, T2DM, Periodontal Disease
- Trial name
- NCT07809477
- Testing
- Health Belief Model-Based Integrated Diabetes-Oral Health Educational Intervention, Standard Diabetes Education and Routine Care
- Volunteers
- 290 people
- Sponsor
- Oman Ministry of Health
Nutrition, Type 2 Diabetes
Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine
This study is designed to test the feasibility and preliminary efficacy of a continuous glucose monitor (CGM)-augmented food is medicine (FIM) intervention for adults with type 2 diabetes and nutrition or food insecurity.
- Conditions
- Nutrition, Type 2 Diabetes, T2DM, T2DM (Type 2 Diabetes Mellitus)
- Trial name
- ALIGN (NCT07148713)
- Testing
- CGM-Augmented FIM, FIM only
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of North Carolina, Chapel Hill
Type II Diabetes Mellitus
A Study to Evaluate the Effect of Musashino Diabetes Diet in Type II Diabetes Mellitus Disease
Evaluation the change of patients' glycosylated hemoglobin (HbA1c) after 12 weeks diet control
- Trial name
- NCT02446054
- Testing
- Musashino T2DM diet
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Celio Technology Inc.
Diabetes Mellitus, Diabetes Mellitus, Type 2
The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Combination with Metformin in Patients With Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control on Metformin Alone.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- NCT05505994
- Testing
- DWP16001, Dapagliflozin
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus (T2DM)
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
This study will assess safety, tolerability, and effect of LIK066 on blood glucose in healthy subjects and in patients with T2DM.
- Trial name
- NCT01407003
- Testing
- LIK066
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus (T2DM), Overweight or Obese
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
The purpose of this study is to assess how fast BGM0504 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT06929156
- Testing
- BGM0504
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Type 2 Diabetes Mellitus (T2DM), Atherosclerosis
Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes
Patients with type 2 diabetes and cardiovascular risk factors are at increased risk of cardiovascular events. Therefore, a multi-center prospective randomized study will be conducted to compare the efficacy and safety of…
- Trial name
- Cilo-Asa (NCT07719894)
- Testing
- Cilostazol, Aspirin
- Where
- South Korea
- Volunteers
- 1,200 people
- Sponsor
- Seoul National University Bundang Hospital
Type 2 Diabetes
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALT-801 and its effects on glucose control in…
- Trial name
- NCT05134662
- Testing
- ALT-801
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Altimmune, Inc.
Type 2 Diabetes Mellitus
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
This study will assess the effect of LCQ when added to metformin.
- Trial name
- NCT00901979
- Testing
- LCQ908A, Sitagliptin, metformin
- Where
- 67 sites in United States, Canada and 3 more
- Volunteers
- 693 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or…
- Trial name
- SURPASS-6 (NCT04537923)
- Testing
- Tirzepatide, Insulin Lispro (U100)
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 1,428 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Salivary Signal Molecules for Neural and Vascular Homeostasis in T2DM
Various signal molecules are detected in blood and tissues of patients with T2DM, that are important for the function of neural tissue in diabetic setting.
- Trial name
- NCT06327503
- Testing
- saliva samples collecting
- Where
- Serbia
- Volunteers
- 24 people
- Sponsor
- University of Belgrade
Type 2 Diabetes (T2DM)
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
This study is a multicenter, randomized, open, parallel-controlled, Phase III clinical study aimed to evaluate the efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes.
- Trial name
- NCT07046273
- Testing
- F027, Ozempic®
- Volunteers
- 496 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Healthy Participants
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants
This study will assess the effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the effect of Erythromycin on AZD5004 in healthy adult male and female participants.
- Trial name
- NCT06948747
- Testing
- AZD5004, Rosuvastatin, Erythromycin
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.
- Trial name
- AWARD-CHN3 (NCT04591626)
- Testing
- Dulaglutide, Insulin Glargine
- Where
- 27 sites in China
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM
Blacks or African Americans have greater risk of and are more likely to die from type 2 diabetes (T2DM). Major barriers to effective diabetes care for Blacks include poor diabetes knowledge, self-management skills, empowerment…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent
- Trial name
- DM-TBSI (NCT00929838)
- Testing
- Diabetes Knowledge/Information, Motivation/Behavioral Skills, Combined Intervention
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- State University of New York at Buffalo
Type 2 Diabetes Mellitus (T2DM), Necrotic Pulp
Photodynamic Therapy in Root Canal Treatment of T2DM Patients: Microbiome Analysis Via Next-Gen Sequencing
This clinical study investigates the effectiveness of antimicrobial photodynamic therapy (aPDT) as an additional disinfection method in root canal treatment of patients with Type 2 Diabetes Mellitus (T2DM) who have apical…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Necrotic Pulp, Apical Periodontitis
- Trial name
- NCT06931678
- Testing
- aPDT
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Chronic Kidney Diseases, Type 2 Diabetes
Burden of Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), and Comorbid T2DM/CKD in Alberta, Canada
The purpose of the research study is to describe the burden of disease among three different cohorts of patients: (1) patients diagnosed with CKD, (2) those with T2DM; and (3) those with T2DM and comorbid CKD.
- Trial name
- NCT04417725
- Testing
- Not applicable - this is a non-interventional, observational study.
- Volunteers
- 588,170 people
- Sponsor
- Medlior Health Outcomes Research Ltd